You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 28, 2015

Animal Feed Control: An Update on Thailand’s Legislation

Subscribe to Updates
Informed Counsel

Thailand’s roadmap of food safety, which was approved in 2004, aims to promote the Kingdom as the “kitchen of the world.” Animal feed, i.e., food given to farm animals, plays a major role in the food safety regime—it is part of the stages of food production, dubbed “farm-to-table,” and is an integral component in the overarching food chain. Animal feed must be as safe as meat for human consumption, and therefore registration, inspection, and control of animal feed are vigorously regulated by the regulatory authorities.

The Department of Livestock Development (DLD), Ministry of Agriculture and Cooperatives (MoAC), is the main authority responsible for putting in place a system for the management and control of animal feed. With the tremendous growth in the animal feed business, a new government unit, the Division of Animal Feed and Veterinary Products Control, was established within the DLD on September 26, 2013. This unit is responsible for the control of animal feed and hazardous substances for use in livestock production, as stipulated in the Animal Feed Quality Control Act and the Hazardous Substance Act, respectively.

Due to the rapid evolution of technology, as well as innovation in animal feed and husbandry, animal feed businesses in Thailand have expanded significantly. Much like the changes in food safety and technology, the law controlling animal feed in Thailand has evolved over time. Animal feed was previously regulated under the Animal Feed Quality Control Act B.E. 2506 (1963 Act). The 1963 Act was replaced with the Animal Feed Quality Control Act B.E. 2525 (1983 Act). Then, in 1999, there was an amendment of the Act. And very recently, the Animal Feed Quality Control Act B.E. 2558 (2015 Act) was announced in the Royal Gazette, which came into force on March 5, 2015.

Under the 2015 Act, “specific control animal feed”  must be registered prior to domestically manufacturing or importing animal feed into the Kingdom of Thailand. This term was not defined under the previous Act. The term is very broad in meaning, as it covers feed that has an impact on socioeconomic problems, feed that will probably harm animals, or feed that will have an effect on consumers of meat.

In the future, the MoAC minister will announce the type, quality standard, conditions, and requirements for registration of such animal feed. The types of animal feed that currently require registration include premix, milk products for animals, feed supplements, feed mixed with veterinary drugs, and more.

Veterinary drugs, on the other hand, are regulated by the Thai Food and Drug Administration. Animal drugs must be registered, following the Drug Act B.E. 2510 (1967), as amended. While a drug product license can be transferred from one juristic person to another, an animal feed registration license cannot be transferred. In addition, if the registered animal feed has not been manufactured or imported for two years, the MoAC minister has the power to revoke the registration license of such animal feed. These are the important precautions that animal feed companies should keep in mind.

The 2015 Act allows officers to inspect premises for the importation or manufacturing of animal feed during the daytime, in cases where unlawful action is suspected. Officers may sample the animal feed in a sufficient quantity for further analysis and testing. Under the 2015 Act, officers are also empowered to issue a requisition letter to call persons to provide testimony or submit documents for further consideration. In addition, the 2015 Act also includes additional provisions regarding the issuance of quality assurance certificates by the DLD and the termination of business.

The 2015 Act is a good sign that the responsible authorities are taking measures to preserve the wellbeing of animals and ensure food safety. Those in the animal feed business should closely monitor animal-feed-related ministerial regulations, which will likely be issued in the near future. It is expected that the 2015 Act will improve the registration and surveillance of animal feed, and ultimately, will ensure greater safety for meat consumers.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
Read More
June 4, 2026
Indonesia’s Minister of Health has issued Decree No. HK.01.07/MENKES/301/2026 on the Affixation of Nutritional Labels and Health Information to Ready-to-Eat Processed Food Products. The decree came into force on April 14, 2026, and was issued to implement the Health Law and Minister of Health Regulation No. 3 of 2026 on Disease Control. The decree requires the inclusion of Nutri-Level labeling on the front-of-pack nutrition labeling (FOPNL) to indicate the product’s nutritional level based on the content of sugar, salt, and fat (“gula, garam dan lemak (GGL)”). Changes from 2024 Draft Regulation The Nutri-Level labeling was previously proposed in 2024 by the Indonesian FDA (BPOM) through a draft regulation concerning nutrition information. While the categories of Nutri-Level labeling remain the same in the issued decree, the content requirements of sugar, salt and fat in the decree are different from the earlier proposal introduced in the 2024 draft BPOM regulation. In addition, the decree has further specified that the content of fat in the Nutri-Level labeling is the content of saturated fat, not total fat as previously proposed in the 2024 draft. The decree requires Nutri-Level labeling to be implemented in beverage products, which is the same as previously proposed in the 2024 draft BPOM regulation. Other food products may gradually become subject to mandatory Nutri-Level labeling under future implementing regulations. Nutri-Level Labeling Food levels as shown by the Nutri-Level labeling are classified into four color-coded categories from A to D: Level A (lowest amount) in dark green Level B in light green Level C in yellow Level D (highest amount) in red The Nutri-Level labeling is represented by the following image. The requirements for each level for sugar, salt, and fat content, based on amounts per 100 milliliters of product in beverage form, are as follows. Nutri-Level information must be
Read More
May 29, 2026
Indonesia’s Food and Drug Authority (BPOM) has issued Regulation No. 7 of 2026 on Drug Promotion and Advertising, establishing an updated framework for promotional activities involving medicinal products in Indonesia. The regulation took effect on April 16, 2026, and supersedes BPOM Regulation No. 2 of 2021 on Drug Advertising Supervision. The new regulation maintains general principles for advertising content, including requirements that advertisements be objective, complete, and not misleading, as further detailed in its annex. It also confirms that advertisements for nonprescription drugs directed to the public must obtain prior approval from BPOM before publication and must be in Bahasa Indonesia. The regulation provides a more comprehensive framework governing how drug promotion is conducted, introducing several notable additions and changes, as described below. Procedure and Requirements for Drug Advertisement Approval To apply for a drug advertisement approval, applicants must create an online account through the dedicated portal SIAPIK. Advertisement approval is available only for registered drugs; unregistered drugs are not eligible for advertisement approval with BPOM. The application must include the advertisement design, along with a translation if the design contains any wording in a foreign language. The submission format varies by media type, requiring, for example, copies in the form of print advertisements for visual media, scripts for audio media, and storyboards for audiovisual media. For online media—including social media—submissions should include any captions, descriptions, and hashtags that form an integral part of the advertising material. The approval timeline takes approximately 3–4 months, as BPOM will generally request additional information or revisions during the verification and evaluation process. Applicants have 20 days to submit any such requested documents. BPOM may also conduct a reevaluation of advertisements that have already received approval, based on monitoring results or new information regarding the safety and quality of the advertised drug. This
Read More